In line with our in vitro findings, gene expression analysis showed that CRC tumor specimens from patients harboring KRAS mutations (n = 217) display significantly higher mRNA expression levels of AATs compared with KRAS WT patients (n = 317) (Fig. 7D–F). This evidence concerns the gene KRAS and neoplasm.